Effectiveness and safety of colistin: Prospective comparative cohort study

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 1019-1027

  Paul, Mical ^a,b   Bishara, Jihad ^a,b   Levcovich, Ariela ^a,b   Chowers, Michal ^b,c   Goldberg, Elad ^a,b   Singer, Pierre ^a,b   Lev, Shaul ^a,b   Leon, Perla ^a   Raskin, Maria ^a,b   Yahav, Dafna ^a,b   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

Author keywords

Acinetobacter; Hospital acquired infections; Klebsiella; Multidrug resistant Gram negative bacteria; Polymyxin

Indexed keywords

COLISTIN; IMIPENEM; MEROPENEM; SULTAMICILLIN; ANTIINFECTIVE AGENT;

ADULT; AGE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORTALITY; NEPHROTOXICITY; NEUROPATHY; PNEUMONIA; PROTEUS INFECTION; RISK FACTOR; SEIZURE; SEPTIC SHOCK; SURGICAL INFECTION; URINARY TRACT INFECTION; AGED; COHORT ANALYSIS; CROSS INFECTION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COLISTIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77953705195     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq069     Document Type: Article

References (27)

1. Koch-Weser J, Sidel VW, Federman EB et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
3. Falagas ME, Fragoulis KN, Kasiakou SK et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26: 504-7.
4. Falagas ME, Rafailidis PI, Ioannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-9.
5. Hachem RY, Chemaly RF, Ahmar CA et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007; 51: 1905-11.
6. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-11.
7. Linden PK, Kusne S, Coley K et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: e154-60.
8. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78-83.
9. Michalopoulos AS, Tsiodras S, Rellos K et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-21.
10. Ouderkirk JP, Nord JA, Turett GS et al. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gramnegative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-62.
11. Betrosian AP, Frantzeskaki F, Xanthaki A et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008; 56: 432-6.
12. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilatorassociated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-8.
13. Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-7.
14. Reina R, Estenssoro E, Saenz G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005; 31: 1058-65.
15. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
16. Paul M, Weinberger M, Siegman-Igra Y et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 2005; 60: 256-60.
17. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54.
18. Leibovici L, Shraga I, Drucker M et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-86.
19. Galani I, Kontopidou F, Souli M et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008; 31: 434-9.
20. Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-8.
21. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 109: c182-7.
22. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59: 786-90.
23. Park YK, Jung SI, Park KH et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009; 64: 43-51.
24. Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36: 807-11.
25. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-6.
26. Bassetti M, Repetto E, Righi E et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008; 61: 417-20.
27. Anon. Urgently needed: new antibiotics. Lancet 2009; 374: 1868.